Save
MANAGEMENT OF RECURRENT DISEASE
ESGO eAcademy, Frederic Amant, 202799
CERVICAL CANCER IMMUNOTHERAPY TRIAL
ESGO eAcademy, Hans W. Nijman, 202804
CONSERVATIVE TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Dimitrios Haidopoulos, 202798
OVARIAN CANCER IMMUNOTHERAPY TRIALS
ESGO eAcademy, Jonathan Ledermann, 202803
RADICAL TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Nicoletta Colombo, 202797
RISK FACTORS AND PATHOGENESIS OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Vesna Kesic, 202796
PRINCIPLES OF IMMUNOTHERAPY
ESGO eAcademy, Christian Marth, 202801
Prognostic Value Of Lymph Node Ratio And Number Of Positive Inguinal Nodes In Patients With Vulvar Cancer
ESGO eAcademy, Richard Schwameis, 202924
ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS
ESGO eAcademy, Frederic Amant, 202790
MECHANISMS OF RESISTANCE IN BRCA MUTATED TUMORS
ESGO eAcademy, Clare Scott, 202793
QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY
ESGO eAcademy, Sarah Blagden, 202788
CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
ESGO eAcademy, Charlie Gourley, 202787
CLINICAL DEVELOPMENT OF OTHER NON PARP TARGETED THERAPIES
ESGO eAcademy, Cristiana Sessa, 202792
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER
ESGO eAcademy, Willemien J. Van Driel, 202786
ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)
ESGO eAcademy, Jonathan Ledermann, 202785
UPDATE ON THE CLINICAL DEVELOPMENT OF PARP INHIBITORS
ESGO eAcademy, Iain McNeish, 202791
CLINICAL TRIALS IN PLATINUM-RESISTANT DISEASE
ESGO eAcademy, Mansoor Mirza, 202781
Vulvar Cancer In Ireland: Analysis Of The Irish National Cancer Registry Over A 20 Year Period
ESGO eAcademy, Ann Rowan, 203117
STRATEGIES FOR OVERCOMING RESISTANCE TO CHEMOTHERAPY
ESGO eAcademy, Sandro Pignata, 202780
PLATINUM-RESISTANT DISEASE: CURRENT STATUS
ESGO eAcademy, Nicole Concin, 202779
RANKL -BONES, SEX, AND BREAST CANCER
ESGO eAcademy, Josef Penninger, 202794
WHY ARE WE FAILING TO CURE OVARIAN CANCER?"
ESGO eAcademy, Christian Marth, 202795
GENERAL IMPLEMENTATION OF IGABT (TRAINING/ MEANS/HEALTH ECONOMICS/RESOURCE LIMITATIONS)
ESGO eAcademy, Christine Haie-Meder, 202775
WHEN, WHY AND HOW TO TEST MISMATCH REPAIR DEFICIENCY IN ENDOMETRIAL CANCER
ESGO eAcademy, Tjalling Bosse, 202778
IMAGE-GUIDED ADAPTIVE BRACHYTHERAPY VERSUS IMRT/STEREOTACTIC RADIOTHERAPY
ESGO eAcademy, Akila Viswanathan, 202774
WHEN, WHY AND HOW TO TEST FOR L1CAM AND P53 EXPRESSION IN ENDOMETRIAL CANCER
ESGO eAcademy, Alain G. Zeimet, 202777
CURRENT STATUS OF IMAGE-GUIDED BRACHYTHERAPY : ONCOLOGICAL RESULTS AND COMPLICATIONS
ESGO eAcademy, Jacob Lindegaard, 202773
WHEN, WHY AND HOW TO TEST POLE MUTATIONAL STATUS IN ENDOMETRIAL CANCER
ESGO eAcademy, David Church, 202776
Interval Between  Cytoreductive Surgery And Adjuvant Chemotherapy Is Associated With Overall Survival In  Patients With Advanced Ovarian Cancer
ESGO eAcademy, Maite Timmermans, 202923
Outcomes Of Robotic Radical Hysterectomy For Cervical Cancer In Comparison To Laparotomy ; A Population Based Study In The United States
ESGO eAcademy, Sabrina Piedimonte, 202922
TREATMENT OF ADVANCED DISEASE, INCLUDING MANAGEMENT OF MORBIDITY
ESGO eAcademy, Alexandra Taylor, 202769
IMPACT OF VAGINAL MORBIDITY ON SEXUALITY AFTER DEFINITIVE RADIOCHEMOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER PATIENTS
ESGO eAcademy, Kathrin Kirchheiner, 202772
ADJUVANT TREATMENT
ESGO eAcademy, Carien Creutzberg, 202768
PHYSICAL CONSEQUENCES OF GYNAECOLOGIC CANCER SURGERY AND THEIR IMPACT ON SEXUAL HEALTH
ESGO eAcademy, Michal Zikan, 202771
DIAGNOSTIC AND SURGICAL MANAGEMENT
ESGO eAcademy, Philippe Morice, 202767
SEXUAL HEALTH IN GYNAECOLOGIC CANCER PATIENTS - PSYCHO-SOCIAL CONSEQUENCES OF DIAGNOSIS AND TREATMENT
ESGO eAcademy, Moniek M ter Kuile, 202770
Cervical Cancer Relapse Rates In Patients With Para-Aortic Negitive PET Scans:A Five-Year Analysis In An Irish Gynaeoncology Centre
ESGO eAcademy, Ann Rowan, 202921
Discussion and Closing
ESGO eAcademy, Sandro Pignata, 202898
Patterns Of Lymph Node Metastases In Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study.
ESGO eAcademy, Lucas Minig, 202920
Future therapies
ESGO eAcademy, Kathleen Moore, 202897
Adjuvant management
ESGO eAcademy, Nicoletta Colombo, 202896
Long-Term Efficacy And Immunogenicity Of The 9-Valent Human Papillomavirus Vaccine: Final Analyses Of A Double-Blind, Randomized Clinical Study
ESGO eAcademy, Elmar A. Joura, 202919
Primary debulking strategy
ESGO eAcademy, Sven Mahner, 202895
REAL-TIME FLUORESCENCE GUIDED-SURGERY WITH ICG FOR SENTINEL LYMPH NODE (SLN) MAPPING IN CASE OF EARLY STAGE CERVICAL OR ENDOMETRIAL CANCER
ESGO eAcademy, Alessandro Buda, 234282
Front-line Ovarian Cancer: Can we do better?: Welcome and introduction
ESGO eAcademy, Sandro Pignata, 202766
Mucinous Ovarian Cancer (MOC): What Is The Reproducibility Of The WHO Classification?
ESGO eAcademy, Mojgan Devouassoux, 202918
Refinement Of High-Risk Endometrial-Cancer (HR-EC) Classification Using DNA Damage Response (DDR) Biomarkers: A Transportec Initiative
ESGO eAcademy, Aurélie AUGUSTE, 202917
PERIOPERATIVE CARE OF THE ELDERLY PATIENT
ESGO eAcademy, Karl Tamussino, 202765
MANAGEMENT OF ADVANCED STAGES AND RECURRENT DISEASE
ESGO eAcademy, Richard Poetter, 202761
Adverse Events After Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Stage III Ovarian Cancer: Phase III OVHIPEC Study
ESGO eAcademy, Simone Koole, 202916
MANAGEMENT OF EARLY STAGES
ESGO eAcademy, David Cibula, 202760
Perioperative Positioning Management In Gynecologic Cancer Surgery: A National NOGGO-AGO Intergroup Survey
ESGO eAcademy, Jenny Katharina Wagner, 202915
WHAT´S NEW IN ANESTHESIA FOR HIGH-RISK PATIENTS: WHAT SURGEONS NEED TO KNOW
ESGO eAcademy, Stephanie Suria, 202763
PATHOLOGY REPORT   
ESGO eAcademy, Maria Rosaria Raspollini, 202759
SHAPING NEW CLINICAL PRACTICE GUIDELINES
ESGO eAcademy, David Cibula, 202758
INITIATING ENHANCED RECOVERY: CHALLENGES AND OPPORTUNITIES
ESGO eAcademy, Lena Wijk, 202762
Hormonal And Fertility Outcome After Fertility Sparing Surgery And Chemotherapy For Ovarian Neoplasms: A Retrospective Study
ESGO eAcademy, Lorenzo Ceppi, 202914
MRI-Based Predictive Factors Of Axillary Lymph Node Metastases In Breast Cancer
ESGO eAcademy, David Atallah, 202913
Experience In Introducing Sentinel Lymph Node Biopsy In Early- Stage Vulva Cancer: A Single Institution Based Prospective Study
ESGO eAcademy, Ligita Paskeviciute Frøding, 202912
ESGO – A STORY OF SUCCESS
ESGO eAcademy, David Cibula, 202757
INTRODUCTION
ESGO eAcademy, Luis M. Chiva, 202756
SUMMARY AND CONCLUSIONS
ESGO eAcademy, Gabriele Calaminus, 202755
TREATMENT OF RECURRENT AND METASTATIC DISEASE
ESGO eAcademy, Ate van der Zee, 202749
CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR
ESGO eAcademy, Cristiana Sessa, 202754
CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR
ESGO eAcademy, Dominik Schneider, 202753
CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA
ESGO eAcademy, Philippe Morice, 202752
CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA
ESGO eAcademy, Gabriele Calaminus, 202751
DIAGNOSIS, STAGING AND PREOPERATIVE WORKUP
ESGO eAcademy, Maaike Oonk, 202747
Practical experiences from CTCA at Southeastern RegionalMedical Center, Georgia USA
ESGO eAcademy, Mansoor Raza Mirza, 202740
Pathological aspects of uterine carcinocarcoma
ESGO eAcademy, Mojgan Devouassoux, 202903
Practical experiences from Klinik für Gynäkologie, Die Charité – Universitätsmedizin Berlin, Germany
ESGO eAcademy, Jacek Grabowski, 202739
CONCLUSION
ESGO eAcademy, Andreas Du Bois, 202736
Q&A and Discussion
ESGO eAcademy, Session Speakers, 203120
SELECTING PATIENTS FOR PARP INHIBITION
ESGO eAcademy, Mansoor Mirza, 202735
RELAPSED OVARIAN CANCER: WHAT DOES MAINTENANCE THERAPY OFFER?
ESGO eAcademy, Nicoletta Colombo, 202733
Welcome and introduction
ESGO eAcademy, Christian Marth, 202732
QUESTIONS REMAINED TO BE ANSWERED
ESGO eAcademy, David Cibula, 202728
CIRCULATING TUMOR CELLS: CHALLENGES & PERSPECTIVES IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Catherine Alix-Panabieres, 202731
SLN IMPLEMENTATION INTO MANAGEMENT ALGORITHMS
ESGO eAcademy, Nadeem Abu Rustum, 202727
DETECTION OF METHYLATED DNA IN VARIOUS BODY FLUIDS AND THEIR USE AS DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TOOLS IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Heidi Fiegl, 202730
DEVELOPMENTS IN DETECTION TECHNIQUES
ESGO eAcademy, Eric Leblanc, 202726
WHOLE-GENOME SEQUENCING OF CELL-FREE DNA IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Adriaan Vanderstichele, 202729
Ultrasound Characteristics Of Endometrial Cancer As Defined By The International Endometrial Tumor Analysis (IETA) Consensus Nomenclature- A Prospective Multicenter Study
ESGO eAcademy, Daniela Fischerova, 202910
LION – LYMPHADENECTOMY IN OVARIAN NEOPLASMS. A PROSPECTIVE RANDOMIZED AGO STUDY GROUP LED GYNECOLOGIC CANCER INTERGROUP TRIAL.
ESGO eAcademy, Domenica Lorusso, 202722
UTERINE CORPUS
ESGO eAcademy, Sigurd Lax, 202725
WHAT MODIFIES THE OUTCOME OF RECURRENT GRANULOSA CELL TUMORS OF THE OVARY?
ESGO eAcademy, Isabel Carriles, 202721
OVARY AND FALLOPIAN TUBE
ESGO eAcademy, Xavier Matias-Guiu, 202724
PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIAL
ESGO eAcademy, Sarah Kitson, 202719
CERVIX, VULVA, VAGINA
ESGO eAcademy, Glenn McCluggage, 202723
Development And Pre-Testing Of The Eortc Quality Of Life Questionnaire For Vulva Cancer Patients – The Significance Of Patient Involvement
ESGO eAcademy, Pernille Jensen, 202909
Closing and remarks
ESGO eAcademy, Andreas Du Bois, 202716
Being Practical Case 3
ESGO eAcademy, Christian Marth, 202715
Being Practical Case 2
ESGO eAcademy, Nicoletta Colombo, 202714
Being Practical Case 1
ESGO eAcademy, Isabelle Ray-Coquard, 202713
SETTING THE SCENE: QUALITY OF LIFE IN OVARIAN CANCER, IS IT A KEY FACTOR FOR OUR DECISION MAKING?
ESGO eAcademy, Felix Hilpert, 202712
Introduction
ESGO eAcademy, Andreas Du Bois, 202711
Prognostic Factors For Local Recurrence Of Squamous Cell Carcinoma Of The Vulva: A Systematic Review
ESGO eAcademy, Nienke Te Grootenhuis, 202908
The New Normal; Sexual Function after Ovarian Cancer for Survivors and Partners Compared to Normdata
ESGO eAcademy, Maria Caroline Vos, 202907
VULVA CANCER
ESGO eAcademy, Ate van der Zee, 202709
The Role Of The Peritoneal Cancer Index In Surgery For Advanced Ovarian Cancer
ESGO eAcademy, Mikkel Rosendahl, 202906

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings